The study allowed enrollment of patients , including those with cirrhosis , with a CD@ + count of @/mm@ or greater or CD@ + percentage of @ % or more and plasma HIV-@ RNA suppressed while taking a stable atazanavir - or raltegravir-inclusive antiretroviral regimen .